Abstract
Colgate-Palmolive will report third-quarter 2026 results on October 30, 2026 Pre-MKt; our preview summarizes consensus revenue of 5.33 billion US dollars and adjusted EPS of 0.93, alongside segment dynamics, margin drivers, and prevailing sell-side expectations for guidance and near-term catalysts.
Market Forecast
Consensus indicates Colgate-Palmolive will deliver revenue of 5.33 billion US dollars this quarter, rising 3.97% year over year, with adjusted EPS expected at 0.93, up 4.21% year over year; EBIT is projected at 1.08 billion US dollars, up 1.18% year over year. Margin forecasts are not explicitly quantified in the consensus inputs we reviewed, though the debate centers on input costs and foreign exchange shaping the near-term earnings cadence relative to prior quarters.
The main business remains centered on Oral, Personal and Home Care, where investors are watching normalization of pricing and promotions, the sell-through of product refreshes, and the pacing of recovery in the United States versus generally steadier international trends. Pet Nutrition is viewed as the most promising segment by many analysts, contributing 1.20 billion US dollars last quarter and expected to remain a relative growth outlier as the company emphasizes premium formulations and vet-channel execution; the 3.97% year-over-year company-level revenue forecast frames the bar for this quarter’s growth contribution from the category.
Last Quarter Review
Colgate-Palmolive posted revenue of 5.36 billion US dollars, a gross profit margin of 61.52%, GAAP net profit attributable to shareholders of 693.00 million US dollars, a net profit margin of 12.93%, and adjusted EPS of 0.99, which increased 7.61% year over year. EBIT rose 5.14% year over year to 1.15 billion US dollars and modestly exceeded consensus by approximately 40.57 million US dollars, reflecting solid operating leverage on pricing and productivity.
By business line, Oral, Personal and Home Care generated 4.17 billion US dollars and Pet Nutrition delivered 1.20 billion US dollars; at the consolidated level, revenue advanced 4.91% year over year. The quarter also featured a 7.28% quarter-on-quarter increase in net profit, highlighting improved operating efficiency as cost relief and mix worked through the P&L.
Current Quarter Outlook
Oral, Personal and Home Care
This business remains the primary top-line driver and the most visible margin swing factor heading into the quarter. After several periods where pricing carried growth, sell-through and scanner data suggest a greater dependence on volume and mix as pricing laps get tougher in developed markets, particularly in the United States. That mix shift puts a premium on innovation and execution of product refreshes; the relaunch cadence across core oral-care SKUs is designed to reinvigorate shelf conversion, with distribution and merchandising support expected to be front-loaded into the back half of 2026.
From a profitability standpoint, gross margin within the segment should continue to benefit from productivity and cost-savings initiatives, though the extent of improvement relative to the prior quarter will be capped by input-cost drift in select commodities and packaging. Promotion intensity has normalized from last year’s low base in several categories; in the near term, higher promotional participation to defend and rebuild share in the U.S. could constrain incremental gross-to-net price realization, making volume recovery a more important lever for meeting consensus. Outside the U.S., execution looks more balanced, and the consolidation of share gains from earlier pricing rounds leaves the brand well positioned to defend mix, but currency translation could trim reported growth if the U.S. dollar remains firm through the quarter close.
Pet Nutrition
Pet Nutrition continues to be identified by the sell side as the company’s most attractive growth platform into late 2026, aided by premiumization, science-backed formulations, and resilient demand in veterinary and specialty channels. Last quarter’s 1.20 billion US dollars revenue base provides a high-quality mix with structurally above-corporate margins, giving this franchise significant influence on consolidated gross margin trajectory when it outgrows the group. Input costs tied to animal fats and proteins have ticked up, which could modestly tighten near-term contribution margin; however, pricing architecture and pack architecture are configured to defend unit economics without materially impairing velocity in core SKUs.
Looking at the quarter, the key questions are the cadence of new-innovation sell-in across priority markets, the sustainment of trade inventory levels after a strong first half, and the balancing act between promotional activity and elasticity in premium tiers. Even if category sell-out is slower than last year’s peaks, the segment’s mix accretion to consolidated margins and cash conversion remains supportive of the earnings algorithm this quarter. Importantly, analysts widely point to this unit as a relative bright spot compared with the more variable dynamics in U.S. mainstream personal care, reinforcing its role as the company’s growth engine through the second half.
Near-term stock drivers
Input costs and foreign exchange are the two most consequential macro variables for this print. Several commodity lines have drifted higher sequentially, including select resins, fats, and packaging substrates, which narrows the pace of gross margin expansion versus the prior quarter; this is consistent with commentary that the lower end of the company’s full-year EPS growth range appears more likely if current cost trends persist. A stronger U.S. dollar also works against reported sales and EBIT in international markets, muting headline growth rates even if local-currency performance remains healthy.
At the micro level, the balance between brand investment and short-term margin is an important debate this quarter. Elevated A&P to support product relaunches and defend shelf position in the U.S. could temporarily weigh on operating margin progression, yet underpins volume and mix necessary for 2027 reacceleration scenarios. Another emerging factor is portfolio shaping: reports indicate the company has explored a potential sale of certain mass-market personal care brands that could fetch more than 1.00 billion US dollars. While any portfolio action is speculative until announced, the market would likely evaluate proceeds and reinvestment options in categories with higher structural growth or margin accretion, which could reshape the medium-term narrative if it materializes.
Finally, guidance tone will be pivotal. Street expectations, as reflected in current-quarter forecasts, are broadly in line with recent run rates. Should management reiterate the full-year outlook with language implying a skew toward the lower end on EPS growth due to input costs and FX, investors may focus on the sustainability of gross margin recovery and the building blocks for 2027. Conversely, any evidence of faster-than-anticipated volume recovery in the U.S., stronger international momentum, or better cost absorption would support the case for continued earnings resilience despite macro headwinds.
Analyst Opinions
The majority of recent opinions are bullish, with buy and overweight ratings outnumbering neutral stances by a wide margin. UBS reiterates a buy rating with a 106 US dollars price target and expects third-quarter results to be broadly in line with Street estimates; its note emphasizes that inflationary pressures and foreign exchange could bias full-year EPS growth closer to the lower end of the guided range, but it also anticipates guidance will be reiterated rather than reset. Goldman Sachs maintains a buy rating with a 100 US dollars target, pointing to durable cash generation and the potential for further mix benefits as innovation supports premium pricing in core categories.
Evercore ISI remains constructive with a 101 US dollars target, highlighting the visibility of gross margin recovery from productivity and price-mix initiatives. Morgan Stanley reiterates overweight and raises its target to 104 US dollars, framing organic sales growth returning toward a 3% to 4% cadence through the back half of 2026 and into 2027, which aligns with the current-quarter consensus revenue growth of 3.97% year over year. BNP Paribas keeps an outperform rating with a 97 US dollars target, while Bank of America maintains a buy at 100 US dollars.
On the neutral side, Wells Fargo holds equalweight at 90 US dollars and Barclays maintains hold at 87 US dollars, reflecting caution around North American category dynamics and valuation relative to history. RBC’s recent work suggests the U.S. business could begin to stabilize in early 2027, which frames the Street’s focus on whether near-term relaunches and promotional posture can narrow share losses ahead of that timeline. Across these perspectives, the bullish cohort dominates in both count and conviction, anchored in three pillars: continued gross margin normalization despite modest cost pressure, the constructive outlook for Pet Nutrition as a margin-accretive growth driver, and optionality from portfolio actions that could simplify the mix and unlock reinvestment capacity.
Synthesizing these views, the prevailing expectation is for an in-line quarter on the P&L with limited changes to full-year parameters, a constructive medium-term earnings trajectory contingent on U.S. execution, and a watch-list of catalysts including cost trends, FX, and any portfolio updates. The tilt toward bullish ratings reflects confidence that the company can defend its price-mix architecture while reigniting volume, with Pet Nutrition providing a cushion to consolidated margins and cash generation even if mainstream personal care in the U.S. remains uneven near term. For this print, the burden of proof sits with North American sell-through, the pace of reinvestment, and management’s tone on cost and currency, but the balance of institutional opinion remains supportive ahead of October 30, 2026.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments